Detalles de la búsqueda
1.
Early onset metastatic colorectal cancer in patients receiving panitumumab-based upfront strategy: Overall and sex-specific outcomes in the Valentino trial.
Int J Cancer
; 151(10): 1760-1769, 2022 11 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-35678328
2.
Reinduction of an Anti-EGFR-based First-line Regimen in Patients with RAS Wild-type Metastatic Colorectal Cancer Enrolled in the Valentino Study.
Oncologist
; 27(1): e29-e36, 2022 02 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-35305093
3.
Baseline neutrophilia, derived neutrophil-to-lymphocyte ratio (dNLR), platelet-to-lymphocyte ratio (PLR), and outcome in non small cell lung cancer (NSCLC) treated with Nivolumab or Docetaxel.
J Cell Physiol
; 233(10): 6337-6343, 2018 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-29672849
4.
Emergence of MET hyper-amplification at progression to MET and BRAF inhibition in colorectal cancer.
Br J Cancer
; 117(3): 347-352, 2017 Jul 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-28654634
5.
Preoperative Capecitabine, Oxaliplatin, and Irinotecan in Resectable Gastric or Gastroesophageal Junction Cancer: Pathological Response as Primary Endpoint and FDG-PET Predictions.
Oncology
; 93(5): 279-286, 2017.
Artículo
en Inglés
| MEDLINE | ID: mdl-28881354
6.
Location of Primary Tumor and Benefit From Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies in Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer.
Oncologist
; 21(8): 988-94, 2016 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-27382031
7.
GNAS mutations as prognostic biomarker in patients with relapsed peritoneal pseudomyxoma receiving metronomic capecitabine and bevacizumab: a clinical and translational study.
J Transl Med
; 14(1): 125, 2016 05 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-27154293
8.
Single-Agent Panitumumab in Frail Elderly Patients With Advanced RAS and BRAF Wild-Type Colorectal Cancer: Challenging Drug Label to Light Up New Hope.
Oncologist
; 20(11): 1261-5, 2015 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-26446234
9.
Undetected toxicity risk in pharmacogenetic testing for dihydropyrimidine dehydrogenase.
Int J Mol Sci
; 16(4): 8884-95, 2015 Apr 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-25906475
10.
BRAF-mutated metastatic colorectal cancer between past and future.
Br J Cancer
; 113(11): 1634-5, 2015 Dec 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-26355234
11.
Maintenance Therapy With Panitumumab Alone vs Panitumumab Plus Fluorouracil-Leucovorin in Patients With RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial.
JAMA Oncol
; 5(9): 1268-1275, 2019 Sep 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31268481
12.
Ramucirumab as Second-Line Therapy in Metastatic Gastric Cancer: Real-World Data from the RAMoss Study.
Target Oncol
; 13(2): 227-234, 2018 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-29582224
13.
Prognostic value of diffuse versus intestinal histotype in patients with gastric cancer: a systematic review and meta-analysis.
J Gastrointest Oncol
; 8(1): 148-163, 2017 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-28280619
14.
Molecular classifications of gastric cancers: Novel insights and possible future applications.
World J Gastrointest Oncol
; 9(5): 194-208, 2017 May 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-28567184
15.
Digital PCR assessment of MGMT promoter methylation coupled with reduced protein expression optimises prediction of response to alkylating agents in metastatic colorectal cancer patients.
Eur J Cancer
; 71: 43-50, 2017 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-27997874
16.
Surrogate Endpoints in Second-Line Trials of Targeted Agents in Metastatic Colorectal Cancer: A Literature-Based Systematic Review and Meta-Analysis.
Cancer Res Treat
; 49(3): 834-845, 2017 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-27857020
17.
Perioperative Triplet Chemotherapy and Cetuximab in Patients With RAS Wild Type High Recurrence Risk or Borderline Resectable Colorectal Cancer Liver Metastases.
Clin Colorectal Cancer
; 16(3): e191-e198, 2017 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-27979717
18.
Heterogeneity of Acquired Resistance to Anti-EGFR Monoclonal Antibodies in Patients with Metastatic Colorectal Cancer.
Clin Cancer Res
; 23(10): 2414-2422, 2017 May 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-27780856
19.
IL-8 and eNOS polymorphisms predict bevacizumab-based first line treatment outcomes in RAS mutant metastatic colorectal cancer patients.
Oncotarget
; 8(10): 16887-16898, 2017 Mar 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-28129643
20.
ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer.
J Natl Cancer Inst
; 109(12)2017 12 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29370427